UGN-103 PDUFA date

The PDUFA goal date for UGN-103 (UGN-103 (mitomycin) for intravesical solution) in recurrent low-grade intermediate risk NMIBC is 14 Jun 2027, as disclosed by UroGen Pharma Ltd. (URGN).

PDUFA date
14 Jun 2027
Condition
recurrent low-grade intermediate risk NMIBC

Drug identity checked against registry records

Also recorded as UGN-103 (mitomycin) for intravesical solution

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder CancerNCT06331299URGNPhase 3Completed2025-09-11Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2027-06-14DayUGN-103UroGen Pharma Ltd. · URGNCompany-disclosed PDUFA goal dateAnnounced review targetrecurrent low-grade intermediate risk NMIBCOpen original source
Read source excerpt

In August 2026, we submitted an NDA for UGN-103 for the treatment of adults with recurrent low-grade intermediate risk NMIBC supported by the clinical data from the ongoing Phase 3 UTOPIA trial, and in October 2026, we announced the FDA's acceptance of the NDA and the assignment of a Prescription Drug User Fee Act ("PDUFA") target action date of June 14, 2027.

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026

2027-06-14DayUGN-103UroGen Pharma Ltd. · URGNCompany-disclosed PDUFA goal dateAnnounced review targetadults with recurrent low-grade intermediate risk NMIBCOpen original source
Read source excerpt

Our NDA for UGN-103 for the treatment of adults with recurrent low-grade intermediate risk NMIBC is presently under review by FDA with a PDUFA target action date of June 14, 2027.

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026

2027-06-14DayUGN-103UroGen Pharma Ltd. · URGNCompany-disclosed PDUFA goal dateAnnounced review targetrecurrent LG-IR-NMIBCOpen original source
Read source excerpt

In October 2026, the FDA accepted for review UroGen’s NDA for UGN-103 and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 14, 2027. The NDA is based on clinical data from the ongoing Phase 3 UTOPIA trial, a single-arm, multicenter trial evaluating the efficacy and safety of UGN-103 in adult patients with recurrent LG-IR-NMIBC.

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026